These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 24762294)

  • 21. Current trends in screening across ethnicities for hypersensitivity to abacavir.
    Rodriguez-Nóvoa S; Soriano V
    Pharmacogenomics; 2008 Oct; 9(10):1531-41. PubMed ID: 18855539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review.
    Cargnin S; Jommi C; Canonico PL; Genazzani AA; Terrazzino S
    Pharmacogenomics; 2014 May; 15(7):963-76. PubMed ID: 24956250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity.
    Norcross MA; Luo S; Lu L; Boyne MT; Gomarteli M; Rennels AD; Woodcock J; Margulies DH; McMurtrey C; Vernon S; Hildebrand WH; Buchli R
    AIDS; 2012 Jul; 26(11):F21-9. PubMed ID: 22617051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR.
    Dello Russo C; Lisi L; Lofaro A; Di Giambenedetto S; Federico B; Madeddu G; Salerno M; Mura MS; Pirazzoli A; de Luca A; Cauda R; Navarra P
    Pharmacogenomics; 2011 Apr; 12(4):567-76. PubMed ID: 21521028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards.
    Rodríguez-Nóvoa S; García-Gascó P; Blanco F; González-Pardo G; Castellares C; Moreno V; Jiménez-Nácher I; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1374-6. PubMed ID: 18184080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-induced alloreactivity: A new paradigm for allorecognition.
    D'Orsogna LJ; Almeida CM; van Miert P; Zoet YM; Anholts JDH; Chopra A; Watson M; Witt C; John M; Claas FHJ
    Am J Transplant; 2019 Sep; 19(9):2606-2613. PubMed ID: 31125485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescription: clinically useful but is it cost-effective in Singapore?
    Kapoor R; Martinez-Vega R; Dong D; Tan SY; Leo YS; Lee CC; Sung C; Ng OT; Archuleta S; Teo YY
    Pharmacogenet Genomics; 2015 Feb; 25(2):60-72. PubMed ID: 25461248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
    Lucas A; Nolan D; Mallal S
    J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HLA- B*5701 Allele in HIV-infected Indian Children and its Association with Abacavir Hypersensitivity.
    Manglani MV; Gabhale YR; Lala MM; Sekhar R; More D
    Indian Pediatr; 2018 Feb; 55(2):140-141. PubMed ID: 29242412
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of methods for in-house screening of HLA-B*57:01 to prevent abacavir hypersensitivity in HIV-1 care.
    De Spiegelaere W; Philippé J; Vervisch K; Verhofstede C; Malatinkova E; Kiselinova M; Trypsteen W; Bonczkowski P; Vogelaers D; Callens S; Ruelle J; Kabeya K; De Wit S; Van Acker P; Van Sandt V; Emonds MP; Coucke P; Sermijn E; Vandekerckhove L
    PLoS One; 2015; 10(4):e0123525. PubMed ID: 25874872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A fluorescence-based sequence-specific primer PCR for the screening of HLA-B(*)57:01.
    Giardina E; Stocchi L; Foti Cuzzola V; Zampatti S; Gambardella S; Patrizi MP; Bramanti P; Pirazzoli A; Novelli G
    Electrophoresis; 2010 Oct; 31(21):3525-30. PubMed ID: 20925049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.
    Rauch A; Nolan D; Martin A; McKinnon E; Almeida C; Mallal S
    Clin Infect Dis; 2006 Jul; 43(1):99-102. PubMed ID: 16758424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing.
    Martin AM; Nolan D; Mallal S
    Tissue Antigens; 2005 Jun; 65(6):571-4. PubMed ID: 15896207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant.
    Martin AM; Nolan D; Gaudieri S; Almeida CA; Nolan R; James I; Carvalho F; Phillips E; Christiansen FT; Purcell AW; McCluskey J; Mallal S
    Proc Natl Acad Sci U S A; 2004 Mar; 101(12):4180-5. PubMed ID: 15024131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study.
    Rauch A; Nolan D; Thurnheer C; Fux CA; Cavassini M; Chave JP; Opravil M; Phillips E; Mallal S; Furrer H;
    Antivir Ther; 2008; 13(8):1019-28. PubMed ID: 19195327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity.
    Chessman D; Kostenko L; Lethborg T; Purcell AW; Williamson NA; Chen Z; Kjer-Nielsen L; Mifsud NA; Tait BD; Holdsworth R; Almeida CA; Nolan D; Macdonald WA; Archbold JK; Kellerher AD; Marriott D; Mallal S; Bharadwaj M; Rossjohn J; McCluskey J
    Immunity; 2008 Jun; 28(6):822-32. PubMed ID: 18549801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful translation of pharmacogenetics into the clinic: the abacavir example.
    Phillips E; Mallal S
    Mol Diagn Ther; 2009; 13(1):1-9. PubMed ID: 19351209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HLA-B*5701 clinical testing: early experience in the United States.
    Faruki H; Heine U; Brown T; Koester R; Lai-Goldman M
    Pharmacogenet Genomics; 2007 Oct; 17(10):857-60. PubMed ID: 17885623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A study of HIV provider attitudes toward HLA-B 5701 testing in the United States.
    Watson ME; Patel LG; Ha B; Wannamaker P; Cuffe R; Shaefer M
    AIDS Patient Care STDS; 2009 Nov; 23(11):957-63. PubMed ID: 19839743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. First external quality assurance program of the Italian HLA-B*57:01 Network assessing the performance of clinical virology laboratories in HLA-B*57:01 testing.
    Meini G; Dello Russo C; Allice T; Barresi R; D'Arrigo R; Falasca F; Lipsi MR; Paolucci S; Zanussi S; Antonetti R; Baldanti F; Basaglia G; Bruzzone B; Polilli E; Ghisetti V; Pucillo LP; Turriziani O; Pirazzoli A; Navarra P; Zazzi M
    J Clin Virol; 2016 May; 78():1-3. PubMed ID: 26946153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.